Warning: Semaglutide Can Cause Lithium Toxicity Through Altered Kidney Clearance

Semaglutide initiation caused lithium toxicity in patients on lithium therapy due to altered renal clearance, highlighting a critical drug interaction for psychiatric patients.

Al-Soleiti, Majd et al.·Journal of clinical psychopharmacology·2025·Preliminary Evidencecase series
RPEP-09832Case seriesPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
case series
Evidence
Preliminary Evidence
Sample
N=very small
Participants
Adults with bipolar disorder on stable lithium regimens who started semaglutide

What This Study Found

Semaglutide initiation caused lithium toxicity in patients on lithium therapy due to altered renal clearance, highlighting a critical drug interaction for psychiatric patients.

Key Numbers

3 patients on stable lithium developed toxicity after semaglutide initiation. Lithium has a narrow therapeutic index requiring careful monitoring.

How They Did This

Clinical or preclinical study with methodology detailed in the full publication.

Why This Research Matters

This finding has implications for the millions of patients using or considering peptide-based therapies.

The Bigger Picture

This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.

What This Study Doesn't Tell Us

Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.

Questions This Raises

  • ?What are the long-term implications of these findings?
  • ?How do these results compare to other studies in this area?
  • ?What further research is needed to confirm and extend these findings?

Trust & Context

Key Stat:
Key finding Semaglutide initiation caused lithium toxicity in patients on lithium therapy due to altered renal c
Evidence Grade:
Evidence grade assessment based on study design and methodology detailed in the full publication.
Study Age:
Published in 2025. Reflects current state of peptide therapeutic research.
Original Title:
Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
Published In:
Journal of clinical psychopharmacology, 45(6), 613-618 (2025)
Database ID:
RPEP-09832

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this study mean for patients?

Semaglutide initiation caused lithium toxicity in patients on lithium therapy due to altered renal clearance, highlighting a critical drug interaction for psychiatric patients.

How reliable are these findings?

The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09832·https://rethinkpeptides.com/research/RPEP-09832

APA

Al-Soleiti, Majd; Leung, Jonathan G; Mubaydeen, Teeba; Markota, Matej; Abulseoud, Osama; Singh, Balwinder; Sola, Christopher L. (2025). Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.. Journal of clinical psychopharmacology, 45(6), 613-618. https://doi.org/10.1097/JCP.0000000000002090

MLA

Al-Soleiti, Majd, et al. "Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.." Journal of clinical psychopharmacology, 2025. https://doi.org/10.1097/JCP.0000000000002090

RethinkPeptides

RethinkPeptides Research Database. "Lithium Toxicity and Altered Clearance Following Initiation ..." RPEP-09832. Retrieved from https://rethinkpeptides.com/research/al-soleiti-2025-lithium-toxicity-and-altered

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.